| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e7b8a7632054e507d98a54cd3d11573 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0478
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F13-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F13-00 |
| filingDate |
2017-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d042ba5652bd391b57b6ca1bb64b60a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0403eaa4a2116ddcda322a860dfb98cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f5210c90ee355872d939297b1272b2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f75ee027f94411970a967460a9c4b813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bee4ae024f81f1d58ebd018177e48819
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_032885fa5400ef95fd2d60def186d989 |
| publicationDate |
2022-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-4083049-A3 |
| titleOfInvention |
99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
| abstract |
This invention relates to a new radiopharmaceutical inhibitor of the prostate-specific membrane antigen (iPSMA) containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing the molecule lipophilicity for coupling to hydrophobic sites of the PSMA, combined with conventional use of HYNIC as a chelating agent for 99m Tc radiometal, where ethylenediamine diacetic acid (EDDA) is used to complete the radiometal coordination sphere. The new 99m Tc-EDDA/HYNIC-iPSMA radiopharmaceutical detects, with high affinity and sensitivity in vivo, the PSMA protein overexpressed in prostate cancer cells by SPECT molecular imaging in nuclear medicine. n The purpose of this invention is to provide a new specific radiopharmaceutical (molecular target radiopharmaceutical) of SPECT with high sensitivity for detection of tumors with PSMA over-expression. |
| priorityDate |
2016-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |